Long Acting, Sustainable Therapies for Opiate Addiction (R01)

archived

-Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute on Drug Abuse, National Institutes of Health, encourages Research Project Grant (R01) applications from institutions/organizations that propose the development of sustained pharmacotherapies and behavioral treatments to reduce the risk of contraction and transmission of HIV. Specifically, this FOA supports applications directed at the development of (1) heroin/morphine-protein conjugates (heretofore referred to as heroin/morphine conjugate vaccines or HCVs) for the treatment of opiate addiction, (2) clinical systems for the application of currently available long-acting (30-day or longer sustained-release) dosage forms for opiate pharmacotherapies to optimize these sustained pharmacotherapies to effect the reduction of the risk for acquisition and transmission of HIV, and (3) effective clinical treatment modalities, including behavioral treatment in conjunction with pharmacotherapies, to improve the effectiveness of opiate treatment and reduce the risk behaviors associated with transmission of HIV. Clinical studies should include the assessment of HIV risk behaviors as an outcome measure. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. NIDA intends to commit initially a total of $4 million for FY 2008 to this Program Announcement to fund 6-8 meritorious applications that address the goals of this FOA. Set-aside funds for future years have not been determined. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

High